Title | Diseases | Cell type | Type of study | Outcome | Cell therapy | Authors |
---|---|---|---|---|---|---|
Intratracheal transplantation of amnion-derived mesenchymal stem cells ameliorates hyperoxia-induced neonatal hyperoxic lung injury via aminoacyl-peptide hydrolase. | Neonatal lung injury | CM- hAMSCs EXO-hAMSCs hAMSCs | Preclinical | ✓ Reducing pulmonary edema and inflammatory cell infiltration | AI effect | Li et al. [1] |
Human amnion-derived mesenchymal stem cells alleviate lung injury induced by white smoke inhalation in rats | Lung injury | hAMSCs | Preclinical | ✓ Reducing lung injury, lung fibrosis, CT score, and inflammation levels | AI and AF effects | Cui et al. [2] |
Nrf2 transfection enhances the efficacy of human amniotic mesenchymal stem cells to repair lung injury induced by lipopolysaccharide | Lung injury | hAMSCs | Preclinical | ✓ Decreasing lung injury, lung fibrosis, and inflammation | AI and AF effects | Zhang et al .[3] |
Conditioned medium from amniotic membrane-derived cells prevents lung fibrosis and preserves blood gas exchanges in bleomycin-injured mice-specificity of the effects and insights into possible mechanisms | Lung fibrosis | CM-hAMSCs | Preclinical | ✓ Decreasing lung fibrosis and preserving the blood gas parameters ✓ Diminishing lung macrophage levels | IM, AI, and AF effect | Cargnoni et al. [4] |
Human amnion epithelial cell transplantation abrogates lung fibrosis and augments repair | Lung fibrosis | hAECs | Preclinical | ✓ Reducing inflammation and lung collagen. | AI and AF effects. Differentiation potential. | Moodley et al. [5] |
Human amnion epithelial cells repair established lung injury | Lung injury | hAECs | Preclinical | ✓ Normalizing lung tissue density, collagen content, and α-SMA production ✓ Diminishing pulmonary leucocytes and fibroblast activation in vitro | AI and AF effects | Vosdoganes et al. [6] |
Title | Diseases | Cell type | Type of study | Outcome | Cell therapy | Authors |
Human amnion epithelial cells mediate lung repair by directly modulating macrophage recruitment and polarization | Lung injury | hAECs | Preclinical | ✓ Reducing macrophage infiltration. ✓ Modulating macrophage polarization | IM and AI effects | Tan et al. [7] |
Human amnion epithelial cells prevent bleomycin-induced lung injury and preserve lung function | Lung injury | hAECs | Preclinical | ✓ Decreasing gene expression of the proinflammatory cytokines ✓ Reducing pulmonary fibrosis and inflammatory cell infiltration | IM, AF and AI effects | Murphy et al. [8] |
Human amnion epithelial cells modulate the inflammatory response to ventilation in preterm lambs | Preterm neonatal lung injury | hAECs | Preclinical | ✓ Modulating the pulmonary inflammatory ✓ Reducing acute lung injury | IM effect | Melville et al. [9] |
Human amnion cells reverse acute and chronic pulmonary damage in experimental neonatal lung injury | Neonatal lung injury | hAECs | Preclinical | ✓ Improving lung architecture. ✓ Reducing macrophages, DC, NK, and pro-inflammatory cytokines. | IM and AI effects. Regenerative property. | Zhu et al. [10] |
Amnion epithelial cell-derived exosomes restrict lung injury and enhance endogenous lung repair | Lung injury | EXO-hAECs | Preclinical | ✓ Improving tissue-to-airspace ratio and reducing lung inflammation and fibrosis. ✓ Stimulating bronchioalveolar stem cell. | IM, AF and AI effects. Regenerative properties. | Tan et al. [11] |
Human amnion epithelial cells as a treatment for inflammation-induced fetal lung injury in sheep | Fetal lung injury | hAECs | Preclinical | ✓ Attenuating lung function and structure. ✓ Reducing proinflammatory cytokines. | AI effect | Vosdogans et al. [12] |
First-in-human administration of allogeneic amnion cells in premature infants with bronchopulmonary dysplasia: a safety study | Broncho- pulmonary dysplasia | hAECs | Clinical phase I | ✓ Administration was safe and tolerated. ✓ No adverse events. (Completed) | - | Lim et al. [13] |
Human amnion cells for the prevention of bronchopulmonary dysplasia: a protocol for a phase I dose escalation study | Broncho-pulmonary dysplasia | hAECs | Clinical phase I | ✓ Safe and adverse events. (Recruiting) | - | Baker et al. [14] |